Hikma PharmaceuticalsHKMPF -2.01%82 3-Year ROIIC % is 8.25 as of Dec. 2025, which is 114% above its 10-year median of 3.85. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 944 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 57.94% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Hikma Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 8.25%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Hikma Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
HKMPF's 3-Year ROIIC % is ranked better than 57.94% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs HKMPF: 8.25
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Hikma Pharmaceuticals 3-Year ROIIC % Related Terms
Hikma Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's 3-Year ROIIC % falls into.
Hikma Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 496.3986 (Dec. 2025) - 395.0954 (Dec. 2022) )
/
( 4931 (Dec. 2025) - 3801 (Dec. 2022) )
=
101.3032
/
1130
=
8.96%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Hikma Pharmaceuticals (HKMPF) has a 3-Year ROIIC % of 8.25 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hikma Pharmaceuticals and its competitors. This is 114% above median its historical median of 3.85. According to the industry distribution chart, Hikma Pharmaceuticals ranks #397 out of 944 companies in the Drug Manufacturers industry, placing it in the top 42.1%.
Is Hikma Pharmaceuticals' 3-Year ROIIC % too high?
Hikma Pharmaceuticals' current 3-Year ROIIC % of 8.25 is 114% above median its 10-year median of 3.85. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Hikma Pharmaceuticals' value of 8.25 is 127% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #397 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #397 out of 944 companies for 3-Year ROIIC %. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. Hikma Pharmaceuticals' value of 8.25 is 127% above this benchmark. While the company's 10-year median is 3.85 vs. the industry median of 3.64, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current 3-Year ROIIC % of 8.25 is 127% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current 3-Year ROIIC % is 8.25, which is 114% above median its own 10-year median of 3.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.52, compared to a current price of $21.26 — trading 25.5% below its estimated fair value. The current 3-Year ROIIC % is 8.25, which is 114% above median its 10-year median of 3.85 and 127% above the Drug Manufacturers industry median of 3.64. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current 3-Year ROIIC % is 8.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.26 is trading 25.5% below its estimated GF Value™ of $28.52.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
3-Year ROIIC %: 8.25 (114% above median its 10-year median of 3.85)
GF Value™: $28.52 vs. price of $21.26 (25.5% below fair value)
Industry Position: 127% above the Drug Manufacturers median (#397 of 944)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
